Company Profile

AnaptysBio, Inc. Stock Price, News & Catalysts

Ticker:
ANAB
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

47.40 USD (+0.72%)

Close

Last updated: November 19, 2026

1.49B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, ANAB closed up 0.72% at $47.40. No new same-company headline was identified in the current news window.

Company overview

Biopharma Royalty Company

Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.

Jemperli Economics

Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers.

Imsidolimab Economics

The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.

Partner-Driven Operating Model

AnaptysBio's future value is primarily linked to regulatory approvals, product sales, milestones and royalties generated by partners. This asset-light structure reduces direct clinical-development activity while preserving exposure to multiple late-stage oncology and inflammatory-disease programs.

Future catalysts

  • FDA action on the Quimilza application for generalized pustular psoriasis by the December 12, 2026 PDUFA date.
  • Regulatory submission for Quimilza in Japan in the first half of 2027.
  • Regulatory submissions for Quimilza in Europe and China in the second half of 2027.
  • European regulatory decision for Quimilza in the second half of 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of AnaptysBio, Inc. (ANAB)?

AnaptysBio, Inc. (ANAB) most recently closed at 47.40 USD, a +0.72% move versus the previous session.

What is the market cap of AnaptysBio, Inc. (ANAB)?

AnaptysBio, Inc. currently has a market capitalization of 1.49B USD on BioPharmSignal.

What does AnaptysBio, Inc. do?

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio. Jemperli Economics Anaptys receives royalties tied to GSK’s Jemperli franchise, including development in endometrial, rectal, colon, and head and neck cancers. Imsidolimab...

On which exchange is ANAB stock listed?

AnaptysBio, Inc. (ANAB) is associated with NASDAQ, United States, Biopharma.

What is imsidolimab?

Imsidolimab Economics The company also retains financial exposure to Vanda’s imsidolimab program in generalized pustular psoriasis.

Which conditions is AnaptysBio, Inc. targeting with imsidolimab?

AnaptysBio, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

How does AnaptysBio, Inc. describe recent progress with imsidolimab?

FDA action on the Quimilza application for generalized pustular psoriasis by the December 12, 2026 PDUFA date. Regulatory submission for Quimilza in Japan in the first half of 2027. Regulatory submissions for Quimilza in Europe and China in the second half of 2027. European regulatory decision for Quimilza in the second half of 2027.

What is Biopharma?

Biopharma Royalty Company Following the spin-off of First Tracks Biotherapeutics, AnaptysBio manages financial collaborations rather than operating an internal drug-development portfolio.